Topical Timolol: a Comparison of Surgical Outcomes
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Observed cosmetic difference of scar in treatment side versus control: Yes or no
研究概览
简要总结
The use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is currently emerging in the literature. The investigators will enroll 30 participants in a split scar study who have their skin cancer surgically removed resulting in a linear wound equal to or longer than 4cm. The objective of this randomized study is to determine the safety and efficacy of 0.25% timolol in promoting wound healing in wound closed primarily greater than or equal to 1.5 cm.
详细描述
Topical timolol has shown in case series to improve healing time and cosmetic outcome of ulcerated or non-healing wounds with improved cosmetic outcome when compared to standard wound care. There is currently no research detailing if this improved outcome is applicable when used with wounds approximated with sutures.
Mechanism of action is not fully elucidated but improved keratinocyte migration and suppression of the inflammatory cascade is thought to improve wound healing. Skin cancer surgeries have morbidity for patients as they are often in cosmetically sensitive locations. Improving cosmetic outcomes of surgical scars could improve patient outcomes and overall satisfaction.
The goal of this study is to determine if topical timolol will improve long-term cosmetic outcomes of surgical scars and thereby improve patient outcomes. There is great variability in how a surgical site heals depending on patient factors as well as surgical site location. The investigators will perform a split scar study to allow each patient to be their own control to account for this variability.
To assess the efficacy and safety of topically applied 0.25% timolol in promoting wound healing in surgical primary linear wound greater than or equal to 4cm versus standard of care (SOC) by:
- Evaluating cosmetic outcomes of surgical wounds in terms of blinded physician and patient assessment at 30 days and 90days following suture removal
- Evaluating patient discomfort by patient questionnaire.
- Determining the side effects associated to 0.25% topical timolol versus SOC;
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •skin wounds greater than or equal to 4cm, closed primarily and linearly following standard excision or Mohs
排除标准
- •Past medical history of psoriasis
- •known history of sensitivity to beta blockers or topical timolol
- •pregnant women
研究组 & 干预措施
Timolol
Timolol 0.25% applied to distal or posterior half of wound edge twice daily prior and adjunct to prior wound care.
干预措施: Timolol 0.25% Ophthalmic Solution (Drug)
Standard Wound Care
Petrolatum ointment
干预措施: Standard Wound Care (Other)
结局指标
主要结局
Observed cosmetic difference of scar in treatment side versus control: Yes or no
时间窗: 3 months after suture removal
Photo review of objective cosmetic difference by blinded physician
次要结局
未报告次要终点
研究者
Keith G. LeBlanc, Jr, MD
Principal Investigator
Louisiana State University Health Sciences Center in New Orleans